Episurf Medical AB (publ) (EPIS-B.ST)
SEK 0.13
(-2.03%)
SEK 0.13
(-2.03%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -87.7 Million SEK | -31.84% |
| 2022 | -71.4 Million SEK | -12.18% |
| 2021 | -63.8 Million SEK | -10.79% |
| 2020 | -58 Million SEK | 9.74% |
| 2019 | -64.3 Million SEK | -17.78% |
| 2018 | -52.4 Million SEK | 8.09% |
| 2017 | -56.9 Million SEK | 1.22% |
| 2016 | -57.61 Million SEK | -38.02% |
| 2015 | -41.73 Million SEK | -34.01% |
| 2014 | -31.15 Million SEK | -43.02% |
| 2013 | -21.78 Million SEK | -43.32% |
| 2012 | -15.19 Million SEK | -264.61% |
| 2011 | -4.16 Million SEK | -56.86% |
| 2010 | -2.65 Million SEK | -395.15% |
| 2009 | -429.02 Thousand SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -19.1 Million SEK | -5.0% |
| 2024 Q3 | -13.4 Million SEK | 29.63% |
| 2024 Q1 | -3.3 Million SEK | 6.25% |
| 2023 Q3 | -17.2 Million SEK | 37.45% |
| 2023 FY | - SEK | -31.84% |
| 2023 Q2 | -27.5 Million SEK | -30.33% |
| 2023 Q4 | -17.7 Million SEK | -2.91% |
| 2023 Q1 | -21.1 Million SEK | 4.95% |
| 2022 Q2 | -17.3 Million SEK | -19.31% |
| 2022 FY | - SEK | -12.18% |
| 2022 Q1 | -14.5 Million SEK | 14.2% |
| 2022 Q4 | -22.2 Million SEK | -48.0% |
| 2022 Q3 | -15 Million SEK | 13.29% |
| 2021 Q3 | -13.9 Million SEK | 11.46% |
| 2021 FY | - SEK | -10.79% |
| 2021 Q2 | -15.7 Million SEK | -4.67% |
| 2021 Q4 | -16.9 Million SEK | -21.58% |
| 2021 Q1 | -15 Million SEK | -6.38% |
| 2020 FY | - SEK | 9.74% |
| 2020 Q3 | -13.4 Million SEK | -10.74% |
| 2020 Q4 | -14.1 Million SEK | -5.22% |
| 2020 Q2 | -12.1 Million SEK | 23.9% |
| 2020 Q1 | -15.9 Million SEK | 7.02% |
| 2019 FY | - SEK | -17.78% |
| 2019 Q1 | -12.1 Million SEK | 11.68% |
| 2019 Q2 | -16.8 Million SEK | -38.84% |
| 2019 Q3 | -15.5 Million SEK | 7.74% |
| 2019 Q4 | -17.1 Million SEK | -10.32% |
| 2018 Q4 | -13.7 Million SEK | -21.24% |
| 2018 FY | - SEK | 8.09% |
| 2018 Q2 | -14.6 Million SEK | -21.67% |
| 2018 Q3 | -11.3 Million SEK | 22.6% |
| 2018 Q1 | -12 Million SEK | 16.89% |
| 2017 Q3 | -12.47 Million SEK | -4.21% |
| 2017 Q2 | -11.96 Million SEK | 33.62% |
| 2017 Q4 | -14.43 Million SEK | -15.79% |
| 2017 Q1 | -18.02 Million SEK | -3.1% |
| 2017 FY | - SEK | 1.22% |
| 2016 Q4 | -17.48 Million SEK | -27.97% |
| 2016 Q3 | -13.66 Million SEK | 11.22% |
| 2016 Q1 | -10.86 Million SEK | 19.34% |
| 2016 Q2 | -15.38 Million SEK | -41.64% |
| 2016 FY | - SEK | -38.02% |
| 2015 Q3 | -10.36 Million SEK | 4.63% |
| 2015 Q1 | -7.03 Million SEK | 7.11% |
| 2015 Q4 | -13.47 Million SEK | -29.98% |
| 2015 FY | - SEK | -34.01% |
| 2015 Q2 | -10.86 Million SEK | -54.42% |
| 2014 Q3 | -6.95 Million SEK | 21.27% |
| 2014 FY | - SEK | -43.02% |
| 2014 Q2 | -8.84 Million SEK | -12.68% |
| 2014 Q1 | -7.84 Million SEK | -35.44% |
| 2014 Q4 | -7.57 Million SEK | -8.85% |
| 2013 Q1 | -5.12 Million SEK | 10.82% |
| 2013 Q2 | -6.39 Million SEK | -24.92% |
| 2013 FY | - SEK | -43.32% |
| 2013 Q4 | -5.79 Million SEK | -29.76% |
| 2013 Q3 | -4.46 Million SEK | 30.23% |
| 2012 Q1 | -3.58 Million SEK | -160.27% |
| 2012 Q2 | -3.28 Million SEK | 8.41% |
| 2012 Q3 | -2.58 Million SEK | 21.16% |
| 2012 Q4 | -5.74 Million SEK | -122.0% |
| 2012 FY | - SEK | -264.61% |
| 2011 Q4 | -1.37 Million SEK | -19.59% |
| 2011 FY | - SEK | -56.86% |
| 2011 Q2 | -2.03 Million SEK | -201.68% |
| 2011 Q1 | -674.12 Thousand SEK | 9.36% |
| 2011 Q3 | -1.15 Million SEK | 43.4% |
| 2010 FY | - SEK | -395.15% |
| 2010 Q2 | -516.27 Thousand SEK | -18.32% |
| 2010 Q4 | -743.74 Thousand SEK | 22.56% |
| 2010 Q1 | -436.34 Thousand SEK | 0.0% |
| 2010 Q3 | -960.44 Thousand SEK | -86.03% |
| 2009 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | -13.716% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 121.292% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 121.292% |
| Arcoma AB | 6.24 Million SEK | 1503.649% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 2.536% |
| BICO Group AB (publ) | 322.3 Million SEK | 127.211% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | 232.921% |
| CellaVision AB (publ) | 207.24 Million SEK | 142.317% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | -28.205% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | -213.853% |
| C-Rad AB (publ) | 48.9 Million SEK | 279.331% |
| Duearity AB (publ) | -24.77 Million SEK | -253.929% |
| Dignitana AB (publ) | -264 Thousand SEK | -33119.697% |
| Getinge AB (publ) | 5.92 Billion SEK | 101.479% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | -30.409% |
| Iconovo AB (publ) | -35.33 Million SEK | -148.193% |
| Integrum AB (publ) | 8.76 Million SEK | 1100.967% |
| Luxbright AB (publ) | -23.86 Million SEK | -267.457% |
| Mentice AB (publ) | 28.87 Million SEK | 403.744% |
| OssDsign AB (publ) | -122.02 Million SEK | 28.127% |
| Paxman AB (publ) | 31.22 Million SEK | 380.829% |
| Promimic AB (publ) | -3.68 Million SEK | -2280.565% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 41.73% |
| SciBase Holding AB (publ) | -51.82 Million SEK | -69.21% |
| ScandiDos AB (publ) | -13.35 Million SEK | -556.634% |
| Sectra AB (publ) | 615.06 Million SEK | 114.259% |
| Sedana Medical AB (publ) | -51.67 Million SEK | -69.718% |
| Senzime AB (publ) | -118.82 Million SEK | 26.193% |
| SpectraCure AB (publ) | -20.96 Million SEK | -318.236% |
| Stille AB | 56.04 Million SEK | 256.493% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 97.246% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | 169.288% |